Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program
A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.
With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…READ MORE
Sandostatin Mobile Administration Program for Carcinoid Syndrome Patients
If you are a carcinoid patient who needs Sandostatin® LAR Depot injections, you may be eligible for the Mobile Administration Program. This program helps alleviate the stress of driving to a doctor’s office (or finding one where you live or while on vacation),…READ MORE